Clinical Trial Update: Effect of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of BAY1002670 (Vilaprisan) [Phase 1]

View source ↗

Summary

Phase 1 study evaluating how hepatic impairment affects the pharmacokinetics, safety, and tolerability of BAY1002670 (Vilaprisan) in patients with uterine leiom…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Uterine Leiomyoma

Drugs mentioned

• BAY1002670 (Vilaprisan) (Vilaprisan)

Snippet

Sponsor: Bayer | Conditions: Leiomyoma | Phase 1 | Status: COMPLETED